Phase II
Yet another busy week for clinical trial news. Here’s a look.
The 643-participant study failed to reach statistical significance in its co-primary cognitive and functional endpoints, ADAS-Cog11 and ADCS-ADL, at end of treatment.
Nuravax is developing an Alzheimer’s vaccine to induce therapeutically potent concentrations of antibodies against pathological proteins. Know more here.
Initial results showed a strong neutralizing antibody response and favorable safety profile among the participants.
It was yet another busy week for clinical trial news. Here’s a look.
Late Thursday, Athira announced that Kawas had resigned from her position as CEO and president of the company.
The FDA placed a clinical hold on Tryp Therapeutics’ Phase IIa trial for eating disorders, including binge eating disorder and hypothalamic obesity.
The designation is based on data from two Phase I trials, which showed the drug to be safe, demonstrating early efficacy.
Redosing is a large and growing concern for gene therapy developers and regulators.
Calithera Biosciences is expanding its oncology portfolio with the addition of two clinical-stage compounds from Takeda Pharmaceuticals.
PRESS RELEASES